JWCTF (JW (Cayman) Therapeutics Co) Cash-to-Debt : 2.28 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. JW (Cayman) Therapeutics Co's cash to debt ratio for the quarter that ended in Jun. 2024 was 2.28.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, JW (Cayman) Therapeutics Co could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Cash-to-Debt or its related term are showing as below:

JWCTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.28 Med: 4.96 Max: 21.28
Current: 2.28

During the past 6 years, JW (Cayman) Therapeutics Co's highest Cash to Debt Ratio was 21.28. The lowest was 2.28. And the median was 4.96.

JWCTF's Cash-to-Debt is ranked worse than
64.63% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs JWCTF: 2.28

JW (Cayman) Therapeutics Co Cash-to-Debt Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

JW (Cayman) Therapeutics Co Cash-to-Debt Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.28

21.28

12.48

4.96

3.16

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial							10.33	4.96	3.26	3.16	2.28

Competitive Comparison of JW (Cayman) Therapeutics Co's Cash-to-Debt

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Cash-to-Debt falls into.

JW (Cayman) Therapeutics Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

JW (Cayman) Therapeutics Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	140.88	/	(16.947	+	27.701)
	=	3.16

JW (Cayman) Therapeutics Co's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	119.789	/	(28.407	+	24.047)
	=	2.28

JW (Cayman) Therapeutics Co (OTCPK:JWCTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

JW (Cayman) Therapeutics Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong JNY:Germany

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co Headlines

No Headlines